株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

HIV/AIDS:治療薬パイプライン分析および2016年までの市場予測

HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016

発行 GlobalData 商品コード 121498
出版日 ページ情報 英文 67 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
HIV/AIDS:治療薬パイプライン分析および2016年までの市場予測 HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016
出版日: 2010年04月30日 ページ情報: 英文 67 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、HIV/AIDS市場について治療薬パイプライン分析および2016年までの市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 HIV/AIDS市場:市場の特徴

  • イントロダクション
  • 疾病の概要
  • 市場規模
  • 市場予測および年複利成長率(CAGR)
  • 市場促進および阻害要因
  • 機会およびアンメットニーズ
  • 要点

第3章 競合のアセスメント

  • 概要
  • 戦略的競合企業の評価
  • 主な市販製品のプロファイル
  • 要点

第4章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプラインの評価
  • 治療:臨床開発中の有望な治療薬
  • 臨床開発中の有望な治療薬の分子プロファイル
  • HIV/AIDS治療市場:作用機序別臨床パイプライン
  • HIV/AIDSパイプライン:主要クラス別医薬品説明
  • HIV/AIDSパイプライン:臨床開発段階別パイプライン
  • 要点

第5章 将来の市場競争についての示唆

第6章 将来の企業

  • イントロダクション
  • Gilead Sciences, Inc
  • Tibotec Pharmaceuticals Ltd
  • Avexa Limited
  • Pharmasset, Inc
  • Achillion Pharmaceuticals, Inc
  • Incyte Corporation
  • Myriad Pharmaceuticals, Inc

第7章 付録

図表

目次
Product Code: GDHCPRT086

Abstract

HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData' s report, “HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has however succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 250 molecules currently in development for various disease segments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

- Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors.
- Analysis of the current and future market competition in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future HIV/AIDS market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global HIV/AIDS market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 HIV/AIDS Market: Market Characterization 6
2.1 Introduction 6
2.2 Disease Overview 7
2.3 HIV/AIDS Market Size 8
2.4 HIV/AIDS Market Forecast and CAGR 9
2.5 Drivers and Barriers for the HIV/AIDS Market 11
2.5.1 Drivers for the HIV/AIDS Market 11
2.5.2 Barriers for the HIV/AIDS Market 13
2.6 Opportunity and Unmet Need 15
2.7 Key Takeaway 17
3 HIV/AIDS Market: Competitive Assessment 18
3.1 Overview 18
3.2 Strategic Competitor Assessment 18
3.3 Product Profiles of the Major Marketed Products in the HIV/AIDS Market 19
3.3.1 Truvada (emtricitabine/tenofovir disoproxil fumarate) 19
3.3.2 Atripla (Efavirenz, Emtricitabine, and Tenofovir) 20
3.3.3 Kaletra (Lopinavir/Ritonavir) 21
3.3.4 Reyataz (Atazanavir sulfate) 22
3.3.5 Sustiva (Efavirenz) 23
3.4 Key Takeaway 25
4 HIV/AIDS Market: Pipeline Assessment 26
4.1 Overview 26
4.2 Strategic Pipeline Assessment 26
4.2.1 Technology Trends Analytic Framework 26
4.3 HIV/AIDS Therapeutics - Promising Drugs under Clinical Development 27
4.4 Molecule Profile for Promising Drugs under Clinical Development 28
4.4.1 Rilpivirine hydrochloride (TMC278) 28
4.4.2 Elvitegravir 29
4.4.3 Apricitabine (ATC) 30
4.4.4 Racivir 31
4.4.5 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 31
4.5 HIV/AIDS Therapeutics Market - Clinical Pipeline by Mechanism of Action 33
4.6 HIV/AIDS Pipeline - Major Different Classes of Drugs Description 33
4.6.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 33
4.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 34
4.6.3 Protease Inhibitors (PIs) 34
4.6.4 Viral Fusion (or Entry) Inhibitors 34
4.6.5 HIV Integrase Strand Transfer Inhibitors 34
4.6.6 Multi-class Combination Products 34
4.6.7 CCR5 Receptor Antagonist 35
4.7 HIV/AIDS Pipeline - Pipeline by Clinical Phases of Development 36
4.7.1 HIV/AIDS Therapeutics - Phase III Clinical Pipeline 36
4.7.2 HIV/AIDS Therapeutics - Phase II Clinical Pipeline 37
4.7.3 HIV/AIDS Therapeutics - Phase I Clinical Pipeline 39
4.7.4 HIV/AIDS Therapeutics - Preclinical Pipeline 41
4.7.5 HIV/AIDS Therapeutics - Early Development Pipeline 42
4.7.6 Discontinued / Suspended Drugs for HIV/AIDS 43
4.8 Key Takeaway 44
5 HIV/AIDS Market: Implications for Future Market Competition 45
6 HIV/AIDS Market: Future Players in the HIV/AIDS Market 47
6.1 Introduction 47
6.2 Gilead Sciences, Inc 47
6.2.1 Company Overview 47
6.2.2 Financial Performance 47
6.2.3 Business Description 48
6.2.4 Viral Infections Portfolio 48
6.2.5 HIV/AIDS Portfolio 49
6.3 Tibotec Pharmaceuticals Ltd 51
6.3.1 Company Overview 51
6.3.2 Viral Infections Portfolio 51
6.3.3 HIV/AIDS Product Portfolio 51
6.4 Avexa Limited 52
6.4.1 Company Overview 52
6.4.2 Financial Performance 53
6.4.3 Business Description 53
6.4.4 Viral Infections Portfolio 53
6.4.5 HIV/AIDS Product Portfolio 54
6.5 Pharmasset, Inc 54
6.5.1 Company Overview 54
6.5.2 Financial Performance 55
6.5.3 Viral Infections Portfolio 55
6.5.4 HIV/AIDS Product Portfolio 55
6.6 Achillion Pharmaceuticals, Inc 56
6.6.1 Company Overview 56
6.6.2 Financial Performance 56
6.6.3 Business Overview 56
6.6.4 Viral Infections Portfolio 57
6.6.5 HIV/AIDS Product Portfolio 57
6.7 Incyte Corporation 57
6.7.1 Company Overview 57
6.7.2 Financial Performance 58
6.7.3 Business Description 58
6.7.4 Viral Infections Portfolio 58
6.7.5 HIV/AIDS Product Portfolio 58
6.8 Myriad Pharmaceuticals, Inc 59
6.8.1 Company Overview 59
6.8.2 Financial Performance 59
6.8.3 HIV Portfolio 59
6.8.4 HIV/AIDS Product Portfolio 59
7 HIV/AIDS Market: Appendix 60
7.1 Market Definition 60
7.2 Abbreviations 60
7.3 Research Methodology 62
7.3.1 Coverage 62
7.3.2 Secondary Research 63
7.3.3 Forecasting 63
7.3.4 Primary Research 66
7.3.5 Expert Panels 66
7.4 Contact Us 66
7.5 Disclaimer 66
7.6 Sources 67

1.1 List of Tables
Table 1: Global HIV/AIDS Market Forecast, 2001-2009 9
Table 2: Global HIV/AIDS Market Forecast, 2009-2016 10
Table 3: HIV Therapeutics Market, Key Drug Going Off Patent, 2009-2016 14
Table 4: Marketed Product Analysis in the HIV/AIDS Market, 2010 24
Table 5: HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development, 2010 27
Table 6: HIV Market, Different Classes of Approved Drugs 35
Table 7: HIV/AIDS Pipeline, Phase III, 2010 36
Table 8: HIV/AIDS Pipeline, Phase II, 2010 37
Table 9: HIV/AIDS Pipeline, Phase I, 2010 39
Table 10: HIV/AIDS Pipeline, Preclinical, 2010 41
Table 11: HIV/AIDS Pipeline, Early Development, 2010 42
Table 12: List of Discontinued Drugs for HIV/AIDS, 2010 43
Table 13: Gilead Sciences - Viral Infections Pipeline, 2010 48
Table 14: Tibotec Pharmaceuticals Ltd - Viral Infections Pipeline, 2010 51
Table 15: Avexa Ltd - Viral Infections Pipeline, 2010 53
Table 16: Pharmasset, Inc - Viral Infections Pipeline, 2010 55
Table 17: Achillion Pharmaceuticals, Inc - Viral Infections Pipeline, 2010 57
Table 18: Incyte Corporation - Viral Infections Pipeline, 2010 58
Table 19: Myriad Pharmaceuticals, Inc - HIV Pipeline, 2010 59

1.2 List of Figures
Figure 1: Global HIV/AIDS Market Forecast, 2001-2009 9
Figure 2: Global HIV/AIDS Market Forecast, 2009-2016 10
Figure 3: Opportunity and Unmet Need in the HIV/AIDS Market, 2010 16
Figure 4: Strategic Competitor Assessment of the Marketed Products for HIV/AIDS, 2010 18
Figure 5: Technology Trends Analytic Framework of the HIV/AIDS Pipeline, 2010 26
Figure 6: Technology Trends Analytic Framework of the HIV/AIDS Pipeline - Description, 2010 27
Figure 7: HIV/AIDS Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010 33
Figure 8: HIV/AIDS Pipeline by Phase of Clinical Development, 2010 36
Figure 9: Implications for Future Market Competition in the HIV/AIDS Market, 2010 45
Figure 10: HIV/AIDS Therapeutics Market - Clinical Pipeline by Company, 2010 47
Figure 11: GlobalData Methodology 62
Figure 12: GlobalData Market Forecasting Model 65

Back to Top